EP0797669A1 - Modeles de criblage - Google Patents

Modeles de criblage

Info

Publication number
EP0797669A1
EP0797669A1 EP95941056A EP95941056A EP0797669A1 EP 0797669 A1 EP0797669 A1 EP 0797669A1 EP 95941056 A EP95941056 A EP 95941056A EP 95941056 A EP95941056 A EP 95941056A EP 0797669 A1 EP0797669 A1 EP 0797669A1
Authority
EP
European Patent Office
Prior art keywords
atpase
helicobacter
gene
dna
coli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95941056A
Other languages
German (de)
English (en)
Inventor
Klaus P. SCHÄFER
Thomas Weitzenegger
Wolfram Steinhilber
Klaus Melchers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4442970A external-priority patent/DE4442970A1/de
Priority claimed from DE1995105645 external-priority patent/DE19505645A1/de
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of EP0797669A1 publication Critical patent/EP0797669A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)

Definitions

  • the invention relates to a screening model for determining the activity of substances which inhibit the P-ATPase activity of Helicobacter.
  • H. pylori is a gastric bacterium that is pathogenic to humans and whose eradication from the stomach is now an essential prerequisite for the permanent cure of H. pylori-associated diseases.
  • the germ is found in the stomach, preferably in and under the mucous membrane, sometimes also between the epithelial cells. Due to the uniqueness of the milieu in which the germ is located, H. pylori must have developed physiological strategies for metabolic changes that enable its survival in the gastrointestinal area of humans.
  • helicobactericidal substances today are largely based on in vitro methods such as the agar dilution test, which can be used to determine the minimum inhibitory concentration with regard to H. pylori growth.
  • helicobacter-infected animals are often used as in vivo models for the screening of helicobactericidal substances.
  • the relatively complex handling of the germ is necessary, which is characterized on the one hand by a relatively slow growth, which is why longer breeding or cultivation times are required, and on the other hand by demanding media conditions (microaerophilia, serum addition is necessary).
  • pylori is human pathogenic (classified as S2 according to the German Federal Disease Law) and its handling is therefore associated with appropriate safety measures and requirements.
  • S2 the German Federal Disease Law
  • helicobactericidal medicinal products there is therefore a great need for simple in vitro primary screening models which can also be used to reduce the use of experimental animals in the primary screening phase.
  • Screening models can be the basis for the development of suitable, safe and efficient forms of therapy for the eradication of this human pathogenic bacterium.
  • the targets of future eradication strategies should be able to be described in their molecular structure and biochemical-physiological significance for the germ in order to ensure a safe and helicobacter-specific effect.
  • recombinant screening models on which the effect of drugs on cloned Helicobacter functions can be investigated, the development and improvement of drugs taking into account drug-target interactions down to the molecular range is possible.
  • An object of the invention is to be seen in the provision of a screening model which allows the primary screening of substances with Helicobacter inhibitory activity without special safety requirements and without the use of experimental animals.
  • the invention therefore relates to a screening model for determining the activity of substances which inhibits the P-ATPase activity of Helicobacter, comprising a) a recombinant organism consisting of at least one host cell which has been transformed via a promoter and can be controlled by a promoter , b) an inducer for gene activation of the P-ATPase, c) cations which only impair the metabolic activity of the recombinant organism in the presence of Helicobacter-P-ATPase, and d) a measuring device for determining the metabolic activity of the recombinant organism.
  • the recombinant organisms that express the specific P-ATPase gene can be used to preferably detect (screen) biological and / or chemical compounds which preferably inhibit the activity of the HP-P-ATPase and for the action on Helicobacter to opume.
  • the host vector system allows screening for substances which interact with the cloned ATPase without having to work primarily with the H. pylori, which is relatively complex to cultivate, and without germs classified according to security level S2.
  • the molecular interaction between protein (target) and inhibitor can be analyzed in a targeted manner on this basis (expression of the mechanism of action or binding) via the expression of specifically mutated ATPase sequences.
  • the system thus also provides the basis for the targeted design of inhibitors (drug development).
  • the isolation of the ATPase genes from the H. pylori genoin and their insertion into bacterial expression vectors and cloning are carried out according to methods known per se.
  • Descendants of E. coli K12 were preferably used as host cells, E. coli MM294 being preferred.
  • plasmids for bacterial expression come into question as bacterial expression vectors.
  • the hybrid Tac promoter from the lae / trp system is preferred, but other promoters such as trc, lac or trp can also be used.
  • PT12-1 is also particularly suitable as an expression plasmid, which is described in detail in Chapter 3.1.2.
  • the model according to the invention for screening for substances which inhibit the P-ATPase activity of Helicobacter consists of a recombinant organism, transformed with at least one Helicobacter-P-ATPase gene, which is expressed from a promoter.
  • the synthesis of the P-ATPase leads in the host cell to sensitivity to media which, in addition to C or N sources, contain a number of ions, including NH ions.
  • This P-ATPase-mediated sensitivity of the host cell is expressed phenotypically by an immediate and significant reduction or change in cellular metabolic activity, which can be measured.
  • This effect on the cellular activity of the recombinant Organism that is found only with expression of the Helicobacter P-ATPase (s) can be prevented, for example, by ortho-vanadate, an inhibitor of P-ATPases.
  • the model is therefore suitable for the screening and improvement of specific inhibitors of Helicobacter P-ATPase (s) that specifically interact with the Helicobacter P-ATPase activity.
  • the function of the model is shown below using the example of a recombinant organism which consists of an E. coli K12 host cell and a recombinant expression plasmid.
  • a P-ATPase was inserted into the plasmid, which was isolated from H. pylori (HP).
  • the derived amino acid sequence of the P-ATPase gene shows in the computer-assisted homology analysis significant similarity with already known bacterial and eukaryotic P-ATPases, in particular with those whose function lies in the transport of divalent cations.
  • the gene or gene product represents a possible target for differential drug therapy of H. pylori-associated diseases.
  • the gene or its recombinant expression in other organisms enables the screening and detection of substances which are the specific gene and / or influence the activity of the correlating gene function, preferably inhibit it.
  • the present invention enables specific and selective primary screening on the basis of a special Helicobacter function (P-ATPase activity) with the aid of recombinant organisms which are classified as non-human pathogens and which are significantly less demanding to handle.
  • P-ATPases are of essential importance for the milieu- or germ-specific ion balance of bacterial organisms such as H. pylori, these represent highly selective targets for differential Helicobacter therapy, through which the germ in its natural habitus through appropriate connections in its vital integrity can be decisively inhibited and killed.
  • All parameters known as a measure of the metabolic activity of bacterial cells are suitable for measuring the metabolic activity of the recombinant organism.
  • the determination of the pH in the immediate vicinity of active cells is particularly suitable.
  • Commercial cytosensor microphysiometers companies. Molecular Devices, Graefelfing
  • the acidification rate i.e. H. the rate at which the medium is acidified by cellular metabolic activity.
  • the 20bp oligonucleotide 1282 represents a mixture of 16 different DNA sequences which code for the DKTGT (I / L) T consensus sequence of P-ATPases.
  • the amino acid sequence is given below in the one-letter and three-letter code above the DNA sequence of the DNA oligonucleotide:
  • the DNA oligonucleotide 1-282 labeled with digoxigenin was first analyzed in Southern blot analyzes with genomic DNA from HP and E. coli, which had previously been restricted with the restriction clononucleases EcoRI, Hind3 and. Ava2 were digested. The DNA oligonucleotide hybridized efficiently with the HP-DNA and was therefore shown to be suitable for subsequent Gcn screeding. 1-282 also hybridized to E. coli DNA, which was of particular importance for the screening strategy. From the AS primary sequence of the P consensus region, further DNA oligonucleotides were derived which code for the DKTGT (l / L) T consensus sequence of P-ATPascn (P region ⁇ P site).
  • DNA oligonucleotide 1-282 1-405 to 1-409 correspond to the entire DNA sequence pool, which includes all possible sequences of this region.
  • oligonucleotides can be used according to the procedure at 1-282 for the detection and isolation of potential P type genes by using the usual labeling and hybridization methods.
  • DNA sequences of the DNA-oligonucleotide mixtures are given below in 5'-3 'direction:
  • GA (TC) AA (AG) AC (AGCT) GG (AGCT) AC (AGTC) AT (TC) AC is 1-405
  • GA (TC) AA (AG) AC (AGCT) GG (AGTC) AC (AGTC) AT (CA) AC is 1-406
  • GA (TC) AA (AG) AC (AGCT) GG (AGTC) AC (AGTC) TT (AG) AC is 1-407
  • GA (TC) AA (AG) AC ( AGCT) GG (AGTC) AC (AGTC) CT (TC) AC is 1-408
  • GA TC
  • AG AC
  • AGCT AGTC
  • AGTC AC
  • CT AG
  • AC DNA oligonucleotide 1-409.
  • Positions in parentheses with multiple bases represent variable positions.
  • the molecules were marked for the hybridization experiments using the digoxigcin 3 'end marking kit (Boehringer Mannheim) in accordance with the manufacturer's instructions. From the direct sequence comparison of these DNA oligonucleotides (1-405 to 1-409) with the base sequence and complexity of the DNA probe 1-282 it can be seen that the probes 1-405 to 1-409 are each significantly more degenerate, i.e. are more variable in their sequence. The greater complexity of these probes, if all of them are used, should make it possible to isolate the entire P type ATPase family.
  • the HP bank was developed by Dr. Rainer Haas (Tübingen) designed and made available.
  • HP gene bank was created on the basis of HP isolate 69A. For this, chromosomal DNA was isolated from HP69A and partially digested with Sau3A. D ⁇ A fragments> 3 kb were enriched by gel electrophoresis.
  • PRH160 was used as the cloning vector (FIG. 1), which has a tetracycline resistance marker (Tet R ).
  • the 2.44 kb plasmid also has a unique Bgl2 cli interface in the polylinker region. This BgI2 site was used to clone the HP-D ⁇ A fragments.
  • the recombinant plasmids were transformed into E. coli HB101 and cloned. 2 x 10 "independent transformants were obtained. After amplification, 200 ⁇ l aliquots with 3.7 x 10 6 cfu (colony forming units) each were filled and stored.
  • the HP-DNA insertions inserted into the plasmid can be double-digested with EcoRI and cut Xhol out of the vector again.
  • the screening was carried out directly on the plasmid DNA.
  • an aliquot from the gene bank was diluted and distributed as an inoculum to 20 culture tubes in such a way that about 70 independent clones from the gene bank were represented in each tube.
  • plasmid preparation was made from each of the 20 "mixed plasmid cultures”. An aliquot of the bacterial cultures was frozen away as glycerol consens. After restriction with EcoRI / Xhol, the plasmid preparations were subjected to a Southern blot analysis with 1-282 as a probe. The plasmid mixture No. 4 gave a clear signal. An aliquot of the corresponding glycerol preserve was therefore plated on LB agar plates. Plasmid preparations were again made from statistically selected colonies, which were examined by means of Southcm blot analysis as in the primary screen. The plasmid preparation No. 39 proved positive. This procedure led to the isolation of plasmid pRH439. 1.3.2. Sequence analysis of the isolated plasmid pRH439
  • the plasmid carries an HPRI insert which can be cleaved with EcoRI-Xhol and is approximately 3.4 kb in length.
  • DNA sequencing led to the result that the HP-specific DNA fragment contains an ORF (Open Reading Frame) of 2058 bp. This codes for a protein of 686 amino acids.
  • 2a-e shows the DNA sequence obtained and the amino acid sequence resulting therefrom.
  • the polypeptide chain contains the conservative box used for the isolation of the gene, which contains the P-site characteristic of P-ATPases.
  • the hydrophobicity analysis shows a whole range of possible transmembrane Hclices, which are necessary for the special membrane topology of the enzyme and which are characteristic of P-ATPases and other membrane enzymes.
  • HP-ATPase A special feature of the isolated HP-ATPase.
  • the high concentration of cysteine and histidine residues is different from the P-ATPases isolated so far. Cys and His residues occur massively in the range from AS position 420 to 550.
  • the enzyme is distinguished by an N-terminal HIHNLDCPDC ion binding site and has an internal CPC motif.
  • This plasmid was isolated from the H. pylori 69A library as described for pRH439. However, the DNA oligonucleotide 1-407 was used as the probe.
  • the DNA sequence was determined using DNA sequencing.
  • the pRH514 insertion DNA was found to extend the DNA sequence of the plasmid pRH439 after 5 '.
  • the reading frame interrupted in pRH439 by the cloning site and preceding the P-type ATPase is completed. Since this gene upstream of the ATPase codes for a protein product and is apparently located on the chromosome of H.pylori 69A adjacent to the described P-type ATPase, the derived gene product was designated as ATPase-associated protein (AA-protcin, in short: AAP) .
  • AA-protcin ATPase-associated protein
  • the AAP-encoding ORF of pRH514 predicts an amino acid chain consisting of 506 residues. 24 bp downstream is the ORF for ATPase 439, which is incomplete in the 3 'range on pRH514, however.
  • the AA protein is characterized by a significant homology to response regulators of bacterial two-component systems. These systems of signal transduction usually consist of a membrane-based sensor kinase and a cytosolic response regulator protein.
  • the AAP from H.pylori shows an identity of approx. 15-20% with E.coli NtrC and K.pneumoniae NifA, two known response regulator proteins, over the entire anioic acid sequence.
  • H.pylori-AAP can be divided into three domains according to the known response regulators: a regulative N-terminal domain with an aspartate residue in position 56, a central domain with a so-called Walker A ATP binding motif (Gly-Ser-Pro -Gly-Cys-Gly-Lys-Ser) and the C-terminal domain with helix-turn-helix molecules, which indicate the possibility of interaction with DNA. It is striking that the central domain of AAP contains four symmetrically arranged Cys residues (positions 358, 360, 370, 372).
  • This DNA clone was isolated from the H.pylori library using DNA probe 1-408.
  • the isolation strategy is under 1.3.1. described.
  • the plasmid contains an H. pylori-specific DNA insertion of approximately 4.5 kbp.
  • the DNA sequence was determined by means of DNA sequencing.
  • the DNA sequence contains 4 complete ORFs (ORFs 2-5) and 2 incomplete permanent, terminal ORFs (ORFI and 6). 4 shows the complete DNA sequence and the deduced amino acid sequences of the corresponding ORFs.
  • ORF 4 encodes another P type ATPase from H.pylori, here called ATPasc-948.
  • the DNA contains an ORF (open reading frame) which codes for a protein consisting of 741 amino acids.
  • the protein has the conserved phosphorylation site required for P-type ATPases.
  • Sequence motifs which are characteristic of P-type ATPases, in particular from the family of metal-ion-transporting p-type ATPases, are contained in the amino acid sequence predicted by pRH948-DNA.
  • the protein is characterized by: a conserved phosphorylation site, an ATP binding region, an N-terminal Cys-x-x-Cys sequence, a Cys-Pro-Cys sequence, associated with a region of hydrophobic amino acids.
  • ATPase948 shows sequences, especially with ATPase439 from H. pylori, the CopA / B-ATPases from Enterococcus hirae, the Cd pump from Staphylococcus aureus (approx. 30% sequence identity).
  • the 607 C-terminal amino acids are characterized by a 93.7% sequence identity with that of Tylor et al. published hpCopA-ATPase from H. pylori.
  • the hpCopA gene product contains no N-terminal Cys-x-x-Cys motif and the putative membrane-associated amino acid triplet Cys-Pro-Cys is also not present in hpCopA. Instead, the sequence Cys-Pro-Ser can be found in hpCopA.
  • the pRH948-encoded ATPase has an N-tc ⁇ ninalale with the characteristic amino acid sequence Cys-x-x-Cys.
  • ATPasc-948 like that of ATPase-439, can be expressed in heterologous form. Suitable for this the methods and strategies described in detail in Chapters 2 and 3. ATPase-948 is also particularly suitable as the basis for the active substance screening model described below using the example of ATPase-439.
  • amino acid sequences of the different ORFs can be seen in FIG. 4.
  • ORF 1 codes for the C-terminal part of a protein and therefore represents a C-terminal partial sequence. This comprises 309 amino acids starting with an aspartate residue and ending with a serine. The sequence starts immediately with the beginning of the insertion DNA.
  • the derived protein product shows significant homology with so-called AAA-type ATPases, which also include the well-studied FtsH protein from E. coli.
  • ORF 2 starts at base position 1162 of the pRH948 DNA sequence. Here is the ATG start codon for methionine.
  • This ORF consisting of a total of 237 triplets, ends at position 1872 with the last base of the terminal alanine triplet.
  • the derived protein is characterized by significant homology to bacterial phosphatidyl serine synthetases (PSS).
  • ORF 3 is localized within ORF 2. It begins with base A at position 1710 as part of the ATG start codon and codes for a peptide of 48 amino acids.
  • ORF 4 codes for the P-type ATPase-948 already described above. This ORF begins at position 1872 of the DNA sequence. The last base of the ORF coding for the PSS homologous protein thus simultaneously represents the starting point of the coding sequence for the P-type ATPase. ORF 4 ends at position 4094. The terminating TGA stop codon follows immediately.
  • ORF 5 immediately follows the TGA stop codon of the P-type ATPase starting with an ATG start codon (base positions 4098-4100).
  • the ORF predicts a protein of 66 amino acids.
  • the protein is characterized by a CxxC motif found in the N-terminal region, CNHC. It is homologous to the CopZ protein, which is part of the Cop operon in Entcrococcus hirae.
  • ORF 6 is incomplete. It begins at position 4401 and terminates after 27 triplets terminates with the end of the hclicobactcr-specific DNA sequence in pRH948. 2. Heterologous expression of Helicobacter gene
  • H.pylori genes can be fully or partially expressed in heterologous systems (bacteria, yeast, eukaryotes).
  • the conventional expression plasmids with bacterial promoters such as e.g. lac, tac and t ⁇ .
  • E.coli kl2 host cells and their derivatives are particularly suitable as host cells.
  • the heterologous expression of H. pylori genes is suitable for the identification and development of helicobactericidal active substances and for the induction of antibodies and antisera.
  • H.pylori-Gcncn The functional expression of essential H.pylori-Gcncn in E.coli is suitable for the construction of screening models, with the help of which special H.pylori enzyme activities can be selectively measured.
  • Such models can be used to identify and develop substances that inhibit the function of the cloned and heterologously expressed H.pvlori-Protcinc and are therefore potentially important as helicobactericidal drugs in the therapy of helicobacter-associated diseases.
  • This procedure leads to the functional and measurable expression of Helicobacter genes in a suitable host cell.
  • the measurability of helicobactic-specific activity is based on a change in the overall metabolic performance of the host cells.
  • the region coding for the Helicobactcr-ATPase was amplified by means of Poh ⁇ ierase chain reaction (PCR) from plasmid pRH439 and inserted and cloned into various bacterial expression vectors with E.coli Tac, Trc or T ⁇ promoters. These include the plasmids pTI2-l, pTrcHisA and pT ⁇ 233. In these vectors, the H. pylori PT ⁇ p ATPase gene is under the control of the promoters indicated. The constructed plasmids were transformed into E. coli K12 strains. For expression, the recombinant E.
  • PCR Poh ⁇ ierase chain reaction
  • the model consists of a recombinant E. coli strain which carries the gene sequence of an H. pylori P-type ATPase, which is controllable in its activity, on an expression plasmid.
  • the medium in which the measurement is carried out must be composed such that the activity of HP-ATPases can be induced and measured therein.
  • the activity of ATPases infiltrated into the host cell influences the general metabolic activity of the host cell and is therefore amenable to measurement.
  • the change in the metabolic activity of the recombinant host cell induced by the P-type ATPase activity can be prevented by inhibiting the P-type ATPase activity.
  • the latter is the basis for using the model for screening and optimizing substances.
  • the host cell is E. coli MM294. This strain is an E. coli 12 derivative and is therefore classified as non-human pathogenic.
  • Expression vector is plasmid PY25. This is composed of the plasmid pTI2-1 and the HP-P type ATPase gene 439.
  • pTI2-1 was constructed from the plasmids pKK223-3 and pGc. ⁇ 2T, both obtained from Pharmacia.
  • the Pstl interface was deleted in the polylinker from pKK.
  • pKK with Pstl cut and the ends treated with T4 DNA polymer crasc.
  • the vector was then digested with Smal, religated and cloned after transformation into E. coli HB101.
  • the cloning product is pKK ⁇ BamHl.
  • the Amp R in pKK ⁇ BamHl was exchanged for the Amp R gene from pBR322, since the latter has an internal Pst 1 interface.
  • pKK ⁇ BamHl and also pBR322 were double digested with Pvul and Ndel.
  • the smaller band (approx. 1.45 kb) was isolated from the pBR322 digest and the large band (approx. 3 kb) from pKK ⁇ Bam.
  • the two DNA fragments were ligated and cloned in E. coli HBIOI.
  • the cloning product is pKK (Pst) ⁇ Bam.
  • pKK (Pst) ⁇ BamH 1 was digested with Pstl and Sspl. The two small DNA bands of approximately 620 and 560 bp were isolated from an agarose gel. pGcx2T was also digested with the enzyme combination Sspl x Pstl. After electrophoretic separation in agaroscgcl, the large 3.2 kb DNA fragment was isolated. The three isolated DNA fragments from pKK (Pst) ⁇ Bam and pGe. ⁇ 2T were ligated and cloned in E. coli HB101. Cloning product is pTI2. This vector contains a Tac promoter, an Amp R gene and the lac repressor gene lacl q . Plasmids with a comparable structure can e.g. B. from Pharmacia (pTrc 99A).
  • pTI2 was linearized with the enzyme combination EcoRI Hind3 and ligated with the double-stranded DNA oligonucleotide MCS1 (Multi Cloning Site 1), which has the corresponding compatible EcoRI or Hind3. After ligation and transformation, plasmid pTI2-1 was obtained. Here MCS1 is cloned behind P Tlc (Tac promoter) into the EcoRI site from pKK.
  • MCS 1 After cloning in pTI2-1, MCS 1 has the sequence 5 '- GAATTCGTAG GAAGCTCATAT GGTCGACTC TAGACCCGGG CTGCAGAAGCTT-3', which offers the restriction sites EcoRI, Ndcl, Sal1, Xbal, Smal, Pstl and Hind3 for the cloning.
  • 5 shows a plasmid map of the constructed expression vector pT12-1.
  • DNA primers 1-404 and 1-402 with the sequences 5'-ACCGA CTTGA ATTCA TGCAA GAATA CCACA TT-3 '(1-404) and 5'- CTGCA ACTCA AGCTT AAGCT CTCAT TGCGC GCAT-3 '(1-402) synthesized.
  • 1-404 corresponds to the first 6 amino acid triplets of the ATPase gene and contains an EcoRI site ("sense" DNA oligonucleotide) upstream.
  • 1-402 corresponds to the last 6 amino acid triplts and contains a TAA stop codon and a Hind3 site ("Antisensc" DNA oligonucleotide).
  • the region from pRH439 (1.3) coding for the HP-ATPase was amplified with these DNA oligonucleotides using polymcrase chain reaction (PCR).
  • PCR polymcrase chain reaction
  • the PCR product was cut with EcoRI and Hind3 in order to release the ends of the clone, and purified on an agarose sail.
  • pTI2-1 was digested with the same enzyme combination (EcoRI and Hind3). Plasmid and PCR product were ligated and cloned in E. coli MM294 after transformation.
  • the cloning product is plasmid PY25.
  • the DNA sequence of the inserted ATPase gene was verified by means of DNA sequencing.
  • the recombinant E. coli strain is called E. coli PY25.
  • the HP-ATPase gene is located in E. coli P Y25 Control of the Tac promoter.
  • the structure of the vector PY25 is given
  • the acidification rate is defined as the rate at which the medium is acidified by cellular metabolic activity.
  • the biological principle of operation of the cytosensor is based on the fact that the H ⁇ concentration in the immediate vicinity of living cells depends on the metabolic activity.
  • the cytosensor is based on a light-controlled sensor (silicon chip), which acts as a highly sensitive and fast pH detector. The sensor is in direct contact with the measuring cell in which the cells are incubated under a manipulable flow of medium.
  • a voltage is applied across the sensor, the current flow being dependent on the proton occupancy of the oxynitrile layer of the silicon chip (McConnel et al., Science 257, 1906-1912, 1992).
  • the sensor detects the smallest metabolic changes in cells that are located in the measuring or sensor chamber.
  • the addition of media, nutrients and test substances is controlled via a computer-controlled system. 8 samples can be measured in parallel.
  • BSS stands for "Balanced Salt Solution", a weakly phosphate-buffered ion solution, and GG for the addition of glucose and glutamine as a source of nutrients and energy.
  • the medium is also (NH 4 ), SO i
  • M9 minimal medium (Molecular Cloning, Maniatis et al., Cold Spring Harbor Laboratory Press, 1989) is inoculated with recombinant E. coli and incubated overnight in a Schüttciinkubator at 37 ° C.
  • the recombinant strain is E. coli PY25.
  • E. coli PTI2-1 which carries the plasmid without the insertion of the ATPase ("empty vector"), is used as the control strain.
  • the measuring chambers of the cytosensor were flooded with BSSGG with 50% pumping power before inserting the sensor chamber. After 10, the prepared sensor chambers with the agarose-fixed cells were inserted. The following parameters were defined:
  • Start Stop Speed is Interval 00:00:00 00:00:40 30%
  • This experimental setup shows the effect of the vanadate as an inhibitor of the induced P-type ATPase and shows that the recombinant E. coli on this basis is screened for substances which interact with the expressed ATPase activity. enables.
  • the plasmid contains a tetracycline resistance marker.
  • the location of the restriction classes for EcoRl, Bglll, Xhol, Kpnl, Smal, Xbal, Clal, Sal l, EcoRV, BamH l. SpH l. Nru l and Pstl is specified.
  • the DNA fragments obtained by partial digestion of genomic H. pylori DNA with Sau3A were cloned into the BglII restriction position of the plasmid.
  • ORF open reading framc from HP-ATPase.
  • the DNA sequence starts with the C of the Xhol (CTCGAG) recognition site in position 1 and ends with the C of the EcoRI (GAATTC) restriction site in position 3410.
  • the ORF which is responsible for an H. pylori P-type ATPase with 686 amino acids encoded, lies between position 1219 with the A of the ATG start codon and position 3275 with the T of the GCT-alanine codon.
  • the ORF is followed by a TAA as a stop codon for translation.
  • the predicted amino acid sequence is shown below the DNA sequence.
  • the consensus sequence containing the phosphorylation site (Asp-388) is underlined.
  • 3a-f show the DNA sequence of the complete pRH514 EcoRI-Xhol insert and the derived ones
  • Amino acid sequence of the complete ORF A oleic acid sequences are given in the one-letter code below the coding region.
  • the complete, 5'-located ORF encodes a protein of 506 amino acids with significant homology to bacterial response regulators.
  • pRH 14 overlaps with DNA clone pRH439. that carries the gene for a P-type ATPase.
  • pRH514 has the 5'-tcil of the ATPase gene 439. Since the complete ORF of pRH514 preceded by ATPase, the response regulator protein encoded on pRH514 was designated as ATPasc-Associates-Protcin (AAP).
  • AAP ATPasc-Associates-Protcin
  • the terminal nuclides which are highlighted by underlining, still correlate with vector DNA.
  • the non-underlined DNA sequence represents the cloned Helicobacter DNA from plasmid pRH948.
  • the H. pylori-specific DNA sequence comprises a total of 6 ORFs. The two outer ones are incomplete, as they are interrupted by the cloning sites and thus merge into the vector DNA sequence.
  • the derived amino acid sequences are given in the one-letter code under the DNA sequence, taking into account all 6 ORFs. The location, type and nature of the ORFs are described in the text.
  • ORF 4 encodes the P-type ATPase-948
  • Fig. 5 plasmid map of PY-25.
  • the basic gate is pTI2-l. This contains a tac promoter
  • P ⁇ TAC> an ampicillin-Rcsistcnz gene (AP ⁇ R>) and a lacI Q gene (LACIQ) which expresses the lac repressor.
  • the P-type ATPase gene (ATPASE) from pRH439 is cloned behind the tac promoter via EcoRI / HindIII restriction enzyme.
  • the vector is suitable for the functional expression of Hclicobaktcr genes in E. coli. The location of the existing unique interfaces of EcoRI, Hind3 and Pstl are given.
  • the sensor chamber B contains recombinant E. coli with plasmid pTI2-1 as a control vector.
  • the sensor chamber F contains recombinant E. coli with the plasmid PY25 with inserted HP-ATPasc-Gcn. The cells were incubated as described in 5.2.4.1. After two hours, IPTG was added to the medium. In the presence of plasmid PY25, the acidification rate of E. coli is greatly reduced.
  • Fig. 7 shows the influence of ortho-vanadate on the acidification rate.
  • the sensor chambers F, G and H contain E. coli with plasmid PY25.
  • ortho-vanadate was added to the medium before induction with IPTG.
  • IPTG (F) or IPTG was added to the medium in the presence of 10 ⁇ M ortho-vanadate.
  • the reduction in the rate of acidification induced by IPTG was not observed in cells pretreated with ortho-vanadate (F, H).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne un modèle de criblage permettant de déterminer l'effet inhibiteur de substances sur l'activité de l'ATPase de type P. Ce modèle comprend (a) un organisme recombiné constitué de cellules hôtes transformées par au moins un gène de l'ATPase de type P pouvant être régulé par un promoteur; (b) un inducteur d'activation génique de l'ATPase de type P; (c) des cations qui affectent l'activité métabolique de l'organisme recombiné uniquement en présence de l'ATPase de type P d'hélicobacter; et (d) un dispositif de mesure déterminant l'activité métabolique de l'organisme recombiné.
EP95941056A 1994-12-02 1995-11-30 Modeles de criblage Withdrawn EP0797669A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4442970 1994-12-02
DE4442970A DE4442970A1 (de) 1994-12-02 1994-12-02 Screening-Modell
DE19505645 1995-02-18
DE1995105645 DE19505645A1 (de) 1995-02-18 1995-02-18 Screening-Modell
PCT/EP1995/004711 WO1996017066A1 (fr) 1994-12-02 1995-11-30 Modeles de criblage

Publications (1)

Publication Number Publication Date
EP0797669A1 true EP0797669A1 (fr) 1997-10-01

Family

ID=25942518

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95941056A Withdrawn EP0797669A1 (fr) 1994-12-02 1995-11-30 Modeles de criblage

Country Status (5)

Country Link
US (1) US5981184A (fr)
EP (1) EP0797669A1 (fr)
JP (1) JPH10509875A (fr)
AU (1) AU4259096A (fr)
WO (1) WO1996017066A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942409A (en) * 1998-07-31 1999-08-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for identification of substances modulating ureI dependent mechanisms of Helicobacter pylori metabolism
AU7511800A (en) * 1999-08-30 2001-03-26 K.U. Leuven Research And Development Novel target for antiparasitic agents and inhibitors thereof
EP1081232A1 (fr) * 1999-08-30 2001-03-07 K.U. Leuven Research & Development Cible nouvelle pour fongicide
WO2023035011A1 (fr) 2021-09-03 2023-03-09 North Carolina State University Compositions et procédés pour conférer une résistance au géminivirus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1258182B (it) * 1992-08-12 1996-02-20 Composizioni contenenti bafilomycina per l'inibizione di vacuolizzazione indotta da helicobacter pylori
DE69424780T2 (de) * 1993-03-27 2001-02-15 University Of Dundee, Dundee Anti-mikrobische agenzien und screening-verfahren dazu

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9617066A1 *

Also Published As

Publication number Publication date
JPH10509875A (ja) 1998-09-29
US5981184A (en) 1999-11-09
AU4259096A (en) 1996-06-19
WO1996017066A1 (fr) 1996-06-06

Similar Documents

Publication Publication Date Title
DE60215461T2 (de) Serpin von bifidobakterien
DE69333110T2 (de) Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
DE60129028T2 (de) Zelluläre arrays zur identifizierung von veränderter genexpression
DE69322166T2 (de) Prüfung auf ein vielfache resistenz gegen antibiotika verursachendes operon
DE60029107T2 (de) Luziferase expressionskassetten und methoden zu ihrer verwendung
DE3789766T2 (de) Verwendung von bakteriellen luciferase strukturellen genen zum klonieren und zur steuerung der genexpression in mikroorganismen, sowie zur etikettierung und identifizierung von genetisch gebildeten organismen.
EP0725792B1 (fr) PROCEDE DE PREPARATION DES PROTEINES PilC RECOMBINANTES
DE69223502T2 (de) Gen für die glykoprotease aus pasteurella haemolytica
DE10124342A1 (de) Verfahren zum Nachweis von Mikroorganismen der Spezies Yersinia pestis/Yersinia pseudotuberculosis und/oder zur Differzierung zwischen Yersinia pestis und Yersinia pseudotuberculosis
EP1588172A2 (fr) Procede pour identifier des proteines, specifiques de la barriere hemato-encephalique (bhe), et des fragments de ces dernieres
DE69535705T2 (de) Funktionelles aufspüren und/oder expressionsvektoren bei mycobakterien
EP0797669A1 (fr) Modeles de criblage
WO1990008836A1 (fr) Procede de depistage du mercure au moyen de micro-organismes dont la bioluminescence augmente en presence de mercure
EP0805204B1 (fr) Protéine récepteur spécifique de l'épididyme et son utilisation
DE3884853T2 (de) Angiogenininhibitoren.
EP1023453B1 (fr) Procede de conditionnement genetique cible pour l'induction d'une transgenese ciblee somatique
DE69432963T2 (de) Plasmid und damit transformierte E. Coli Stämme
EP1007671B1 (fr) Gene ii de fanconi
DE69424780T2 (de) Anti-mikrobische agenzien und screening-verfahren dazu
WO1992011370A2 (fr) Polypeptides derives de proteines du virus de l'hepatite c
EP2217262B1 (fr) Fragments d'ifapsoriasine à terminaison c en tant que peptides antimicrobiens et leur utilisation dans le traitment des infections de pseudomonas
EP0842278B1 (fr) Proteine a activite de desoxyribonuclease
DE69823712T2 (de) Rab3 GEP Protein
DE19505645A1 (de) Screening-Modell
DE69735885T2 (de) Erkennung von pyrazinamid-resistenten mycobakterien und verfahren zur behandlung von mycobakterien-infektionen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALTANA PHARMA AG

17Q First examination report despatched

Effective date: 20030820

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040313